First human test for kidney disease drug begins
NCT ID NCT06863467
Summary
This early-stage study tested the safety and side effects of a single dose of an experimental drug called Gemini in 40 adults with moderate to severe chronic kidney disease. Researchers compared Gemini to a placebo (inactive substance) to see how well it was tolerated and how the body processed it. The main goal was to find a safe dose for future studies, not to treat or cure the kidney disease itself.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Institute of Renal Research
Chula Vista, California, 91911, United States
-
California Institute of Renal Research
La Mesa, California, 92942, United States
-
Clinical Advance Center, PLLC
San Antonio, Texas, 78212, United States
Conditions
Explore the condition pages connected to this study.